Evaluation of the combination of FLT3-ITD and VEGFC expression among AML with intermediate-risk cytogenetics. Evaluation of the combination of FLT3-ITD and VEGFC expression level among patients with AML with intermediate-risk cytogenetics. (A) OS and EFS (B) are shown for the 4 subgroups divided by FLT3-ITD and VEGFC status. High VEGFC indicates a VEGFC expression level above the median VEGFC level in the specific patient group, whereas low VEGFC indicates a VEGFC expression level below the median VEGFC level in the specific patient group. The low and high VEGFC without FLT3-ITD subgroups consist of 108 patients per group and the low and high VEGFC with FLT3-ITD subgroups consist of 57 patients per group. P values are given for the overall comparison across all 4 groups.